Result of AGM
RNS & Investor News
Non-exclusive agreement with Smart For Life
04 May 2020
Launch of SlimBiome® containing products in the USA and Canada
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high
cholesterol, diabetes and skincare, announces that the Company has entered into a non-exclusive license agreement for its SlimBiome® trademark with Smart For Life, Inc. ("Smart For Life") and related launch of cookies containing OptiBiotix's SlimBiome® proprietary weight management technology in the USA and Canada. The license is contingent on an annual minimum order quantity and the first order within thirty days of signing the agreement.
Smart For Life (https://www.smartforlife.com) is a US-based company that was founded in 2002 by Dr. Sasson Moulavi, a bariatric doctor. Smart For Life develops and sells scientifically formulated weight management solutions that balance fibre, protein and complex carbohydrates to help naturally suppress appetite and works with natural ingredients which are scientifically backed.
This is another commercial strategic step by OptiBiotix to facilitate customer access to its award-winning SlimBiome® technology as the Smart For Life cookies are available online; at Walmart in the USA and soon at Costco in Canada.
Dr. Fred Narbel, Managing Director of Optibiotix's prebiotics division, commented: "We are very pleased to have signed an agreement with Smart For Life to use our award-winning weight management technology and related trademark to market and commercialise products containing SlimBiome® in the USA and Canada. Smart For Life are an ideal partner because they understand the science behind SlimBiome® and are able to explain the value proposition clearly to their customers and distributors. Moreover, this commercial launch builds on the manufacturing agreement signed with Agropur to produce SlimBiome® in North America (RNS: 24 June 2019) as it provides Smart For Life with a local source of supply."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
|OptiBiotix Health plc||www.optibiotix.com|
|Stephen O'Hara, Chief Executive||Contact via Walbrook below|
|Cairn Financial Advisers LLP (NOMAD)||Tel: 020 7213 0880|
|Liam Murray / Jo Turner / Ludovico Lazzaretti|
|finnCap (Broker)||Tel: 020 7220 0500|
|Geoff Nash / Kate Bannatyne (Corporate Finance)|
|Camille Gochez (Corporate Broking)|
|Walbrook PR Ltd||Mob: 07876 741 001|
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020